Esperion Therapeutics (ESPR) Preferred Stock Liabilities (2012 - 2013)
Esperion Therapeutics (ESPR) posted Preferred Stock Liabilities of $57.5 million for Q2 2013, up 139.74% on a QoQ basis from $24.0 million in Q4 2012.
Esperion Therapeutics (ESPR) Preferred Stock Liabilities (2012 - 2013) Analysis & Trends
Esperion Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $57.5 million for Q2 2013.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $57.5 million in Q2 2013, while the trailing twelve-month figure through Jun 2013 was $57.5 million (changed N/A YoY) and the FY2012 annual result came in at $24.0 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities was $57.5 million for Q2 2013 at Esperion Therapeutics, up from $24.0 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $57.5 million in Q2 2013 and bottomed at $24.0 million in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2013 | 57.48 Mn |
| Dec 31, 2012 | 23.98 Mn |